Protagonist Therapeutics, Inc.
PTGX
शेयरों में रैंक
#2194
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
शेयर मूल्य
$139.45
मार्केट कैप
$9.02B
बदलाव (1 दिन)
0.99%
बदलाव (1 वर्ष)
89.73%
देश
US
व्यापार Protagonist Therapeutics, Inc. (PTGX)
श्रेणी
Healthcare
Protagonist Therapeutics, Inc. (PTGX) के लिए स्टॉक मूल्य इतिहास
दिन का सबसे उच्च समापन मूल्य: $138.63 (2026-10-01 को)
दिन का सबसे निम्न समापन मूल्य: $11.34 (2016-08-01 को)
दिन का सबसे निम्न समापन मूल्य: $11.34 (2016-08-01 को)
Protagonist Therapeutics, Inc. के स्टॉक मूल्य का इतिहास 2016 से 2026 तक
प्रत्येक वर्ष के अंत में स्टॉक मूल्य प्रदर्शन
| वर्ष | प्रदर्शन |
|---|---|
| 2026 (TTM) | 21.88% |
| 2025 | 119.26% |
| 2024 | 92.93% |
| 2023 | 131.51% |
| 2022 | -72.05% |
| 2021 | 46.48% |
| 2020 | 203.82% |
| 2019 | 9.00% |
| 2018 | -65.01% |
| 2017 | -15.57% |
| 2016 | 0.00% |
समान कंपनियों या प्रतिस्पर्धियों के स्टॉक मूल्य
| कंपनी | स्टॉक मूल्य | परिवर्तन 1व% | देश |
|---|---|---|---|
| $536.13 | 25.72% |
US
|
|
| $200.12 | 645.31% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $880.01 | 8.09% |
NL
|
